GLP-3
Recent research & studies
- Primary signet-ring carcinoma of the urinary bladder: A case report and mini review of literature.
Primary signet ring cell carcinoma (SRCC) of the urinary bladder is an exceptionally rare and aggressive malignancy. We report a case of a 60-year-old man presenting with painless gross hematuria, urinary frequency, and dysuria. Imaging and cystoscopy revealed a bladder…
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive…
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.
Peptide-based therapeutics such as tirzepatide and semaglutide target the neuroendocrine system to remediate both diabetes and obesity. In addition to integrating the complementary actions of two endogenous metabolically related hormones targeting glucagon-like peptide-1 and glucagon receptors (GLP-1R and GCGR), the…
- Correction to: Modern and multidisciplinary care in polycythemia vera.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
- Retatrutide and the urinary tract infection signal: Is the answer hidden in timing?
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher…
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), are strongly linked to obesity, insulin resistance, type 2 diabetes, and progressive liver fibrosis. Dual and triple glucagon-like peptide-1 (GLP-1)-based polyagonists may provide complementary hepatic and…
These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.
